Enzian Pharmaceutics demonstrates that its expandable fibrous dosage forms enhance the bioavailability of sparingly-soluble drugs

Upon ingestion, the new Enzian dosage form resides in the stomach for several hours and steadily delivers drug into the blood. This enables enhanced effectiveness of many life-saving drug therapies.
MarketWatch

Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

The MarketWatch News Department was not involved in the creation of this content. MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and ...
Morningstar

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

The pharmaceutical sector is at a critical turning point as it becomes increasingly clear that even the most powerful cancer treatments depend on how effectively they reach tumors in therapeutic ...
Morningstar

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential ...
Nature

Gastroretentive Drug Delivery Systems

Gastroretentive drug delivery systems (GRDDS) represent a sophisticated approach to oral medication by extending the retention time of dosage forms in the stomach. This increased residence time can ...

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

Centre scraps prior approval system for BA/BE studies of low-risk drugs

The Centre has removed prior approval requirements for low-risk BA/BE studies meant for exports, aiming to cut regulatory ...
Nasdaq

Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today ...